Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 401–500 of 1,015
Yao, S., Xu, F., Wang, Y., Shang, J., Li, S., Xu, X., Liu, Z., He, W., Guo, Z., & Chen, Y. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c17268 · Cited by 127
Ma, D., Bian, H., Gu, M., Wang, L., Chen, X., & Peng, X. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215677 · Cited by 124
Wang, H., Guo, Y., Wang, C., Jiang, X., Liu, H., Yuan, A., Yan, J., Hu, Y., & Wu, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120621 · Cited by 124
The Tumor Microenvironment and Strategies to Improve Drug Distribution
Saggar, J. K., Yu, M., Tan, Q., & Tannock, I. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00154 · Cited by 123
Drewitz, M., Helbling, M., Fried, N., Bieri, M., Moritz, W., Lichtenberg, J., & Kelm, J. M. (2011) · Biotechnology Journal · doi:10.1002/biot.201100290 · Cited by 124
Copper isotope effect in serum of cancer patients. A pilot study
Télouk, P., Puisieux, A., Fujii, T., Balter, V., Bondanese, V. P., Morel, A., Clapisson, G., Lamboux, A., & Albarède, F. (2014) · Metallomics · doi:10.1039/c4mt00269e · Cited by 131
Biological determinants of radioresistance and their remediation in pancreatic cancer
Seshacharyulu, P., Baine, M. J., Souchek, J. J., Menning, M., Kaur, S., Yan, Y., Ouellette, M. M., Jain, M., Lin, C. H., & Batra, S. K. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.003 · Cited by 132
Pan, Y., Tang, W., Fan, W., Zhang, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01145f · Cited by 131
Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy
Gkretsi, V., Stylianou, A., Papageorgis, P., Polydorou, C., & Stylianopoulos, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00214 · Cited by 123
Voutouri, C., Polydorou, C., Papageorgis, P., Gkretsi, V., & Stylianopoulos, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.10.001 · Cited by 139
Wang, Z., Ma, L., Su, M., Zhou, Y., Mao, K., Li, C., Peng, G., Zhou, C., Shen, B., & Dou, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0223-0 · Cited by 126
CO2-sensitive tRNA modification associated with human mitochondrial disease
Lin, H., Miyauchi, K., Harada, T., Okita, R., Takeshita, E., Komaki, H., Fujioka, K., Yagasaki, H., Goto, Y., Yanaka, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04250-4 · Cited by 125
Ahechu, P., Zozaya, G., Martí, P., Hernández-Lizoáin, J. L., Baixauli, J., Unamuno, X., Frühbeck, G., & Catalán, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02918 · Cited by 143
Ghini, V., Laera, L., Fantechi, B., Monte, F. D., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020) · Cancers · doi:10.3390/cancers12123574 · Cited by 139
Extracellular Matrix Remodeling and Stiffening Modulate Tumor Phenotype and Treatment Response
Leight, J. L., Drain, A. P., & Weaver, V. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034431 · Cited by 131
Benito, J., Shi, Y., Szymanska, B., Carol, H., Boehm, I., Lu, H., Konoplev, S. N., Fang, W., Zweidler‐McKay, P. A., Campana, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023108 · Cited by 130
Self-citationACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Gerstner, E. R., Zhang, Z., Fink, J. R., Muzi, M., Hanna, L., Greco, E., Prah, M., Schmainda, K. M., Mintz, A., Kostakoglu, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2529 · Cited by 122
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 136
Limitations of Anti-Angiogenic Treatment of Tumors
Ribatti, D., Annese, T., Ruggieri, S., Tamma, R., & Crivellato, E. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.022 · Cited by 141
Exploring the Phototoxicity of Hypoxic Active Iridium(III)-Based Sensitizers in 3D Tumor Spheroids
Bevernaegie, R., Doix, B., Bastien, E., Diman, A., Decottignies, A., Féron, O., & Elias, B. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b07723 · Cited by 124
Weerasekara, V. K., Panek, D. J., Broadbent, D. G., Mortenson, J. B., Mathis, A. D., Logan, G. N., Prince, J. T., Thomson, D. M., Thompson, J. W., & Andersen, J. L. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00740-14 · Cited by 120
Targeting tumor associated macrophages (TAMs) via nanocarriers
Singh, Y., Pawar, V. K., Meher, J. G., Raval, K., Kumar, A., Shrivastava, R., Bhadauria, S., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.395 · Cited by 127
Wang, P., Wang, X., Luo, Q., Li, Y., Lin, X., Fan, L., Zhang, Y., Liu, J., & Liu, X. (2019) · Theranostics · doi:10.7150/thno.29817 · Cited by 121
Ni, K., Lan, G., Song, Y., Hao, Z., & Lin, W. (2020) · Chemical Science · doi:10.1039/d0sc01949f · Cited by 121
Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A., & Podhajcer, O. L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4367 · Cited by 120
Hypoxia Activation of Mitophagy and Its Role in Disease Pathogenesis
Wu, H., & Chen, Q. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6204 · Cited by 124
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
Scharping, N., & Delgoffe, G. (2016) · Vaccines · doi:10.3390/vaccines4040046 · Cited by 120
Role of Microenvironment in Glioma Invasion: What We Learned from In Vitro Models
Manini, I., Caponnetto, F., Bartolini, A., Ius, T., Mariuzzi, L., Loreto, C. D., Beltrami, A. P., & Cesselli, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010147 · Cited by 139
Stepwise Degradable Nanocarriers Enabled Cascade Delivery for Synergistic Cancer Therapy
Yang, Y., Lu, Y., Abbaraju, P. L., Azimi, I., Lei, C., Tang, J., Jambhrunkar, M., Fu, J., Zhang, M., Liu, Y., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800706 · Cited by 120
Hypoxia-Triggered Nanoscale Metal–Organic Frameworks for Enhanced Anticancer Activity
Liu, M., Wang, L., Zheng, X., Liu, S., & Xie, Z. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b07570 · Cited by 120
van Rixel, V. H. S., Ramu, V., Auyeung, A. B., Beztsinna, N., Leger, D. Y., Lameijer, L. N., Hilt, S. T., Dévédec, S. E. L., Yıldız, T., Betancourt, T., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b07225 · Cited by 117
Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G. M., Coveler, A. L., Bueso‐Ramos, C. E., Benito, J., Konoplev, S. N., Gu, Y., Ravandi, F., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118455 · Cited by 134
Self-citationEde, C., Chen, X., Lin, M.-Y., & Chen, Y. Y. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00266 · Cited by 130
Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment
Chu, C., Su, M., Zhu, J. X., Li, D., Cheng, H., Chen, X. S., & Liu, G. (2019) · Theranostics · doi:10.7150/thno.33539 · Cited by 120
Luo, Z., Tian, H., Liu, L., Chen, Z., Liang, R., Chen, Z., Wu, Z., Ma, A., Zheng, M., & Cai, L. (2018) · Theranostics · doi:10.7150/thno.25409 · Cited by 119
Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents
Qiu, H., Wang, P., Lin, H., Tang, C., Zhu, H., & Yang, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13141 · Cited by 118
Yang, G., Tian, J. H., Chen, C., Jiang, D., Xue, Y., Wang, C., Gao, Y., & Zhang, W. (2019) · Chemical Science · doi:10.1039/c9sc00985j · Cited by 118
Porphyrin‐Based Metal−Organic Framework Compounds as Promising Nanomedicines in Photodynamic Therapy
Yu, W., Zhen, W., Zhang, Q., Yan-chun, L., Luo, H., He, J., & Liu, Y. (2020) · ChemMedChem · doi:10.1002/cmdc.202000353 · Cited by 120
Goel, S., Gupta, N., Walcott, B. P., Snuderl, M., Kesler, C. T., Kirkpatrick, N. D., Heishi, T., Huang, Y., Martin, J. D., Ager, E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt164 · Cited by 117
Advances in nanomaterials for treatment of hypoxic tumor
Zou, M., Liu, W., Chen, H., Bai, X., Gao, F., Ye, J., Cheng, H. L., & Zhang, X. (2020) · National Science Review · doi:10.1093/nsr/nwaa160 · Cited by 124
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
Chen, C., Yang, Y., Wang, Z., Li, H., Dong, C., & Zhang, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00302 · Cited by 109
HypoxamiRs and Cancer: From Biology to Targeted Therapy
Gee, H. E., Ivan, C., Calin, G. A., & Ivan, M. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5639 · Cited by 116
Shan, L., Fan, W., Wang, W., Tang, W., Yáng, Z., Wang, Z., Liu, Y., Shen, Z., Dai, Y., Cheng, S., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b02477 · Cited by 116
Recent progress in the augmentation of reactive species with nanoplatforms for cancer therapy
Wu, M., Ding, Y., & Li, L. (2019) · Nanoscale · doi:10.1039/c9nr06651a · Cited by 116
Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer
Pucelik, B., Sułek, A., Barzowska, A., & Dąbrowski, J. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.007 · Cited by 123
Combinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 128
Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent
Wen, L., Liang, C., Chen, E., Chen, W., Liang, F., Zhi, X., Wei, T., Xue, F., Li, G., Yang, Q., et al. (2016) · Scientific Reports · doi:10.1038/srep23269 · Cited by 115
Schöning, J. P., Monteiro, M., & Gu, W. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12693 · Cited by 115
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115
Prodrug Applications for Targeted Cancer Therapy
Giang, I., Boland, E. L., & Poon, G. M. K. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9638-z · Cited by 113
Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Rey, S., Schito, L., Wouters, B. G., Eliasof, S. D., & Kerbel, R. S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.002 · Cited by 122
19F Magnetic Resonance Activity-Based Sensing Using Paramagnetic Metals
Xie, D., Yu, M., Kadakia, R. T., & Que, E. L. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00352 · Cited by 119
Park, Y., Huh, K. M., & Kang, S.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052491 · Cited by 114
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113
Bioreductive fluorescent imaging agents: applications to tumour hypoxia
Elmes, R. B. P. (2016) · Chemical Communications · doi:10.1039/c6cc01037g · Cited by 116
Mi, C., Ma, J., Wang, K. S., Zuo, H. X., Wang, Z., Li, M. Y., Piao, L. X., Xu, G. H., Li, X., Quan, Z. S., et al. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.03.033 · Cited by 122
Metabolomic signature of brain cancer
Pandey, R., Caflisch, L., Lodi, A., Brenner, A. J., & Tiziani, S. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22694 · Cited by 134
Lin, Y.-J., Chuang, E., Cheng, Y., Anilkumar, T. S., Chen, H., & Chen, J. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.05.055 · Cited by 115
Nanoparticle Interactions with the Tumor Microenvironment
Huai, Y., Hossen, M. N., Wilhelm, S., Bhattacharya, R., & Mukherjee, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00448 · Cited by 113
Metformin-based nanomedicines for reprogramming tumor immune microenvironment
Liu, J., Li, X., Li, Y., Gong, Q., & Luo, K. (2024) · Theranostics · doi:10.7150/thno.104872 · Cited by 123
Zhou, C., Ye, L., Jiang, C., Bai, J., Chi, Y., & Zhang, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3453-8 · Cited by 116
Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., van Stiphout, R. G. P. M., Yaromina, A., Sun, J. D., Hart, C. P., Windhorst, A. D., van Elmpt, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0018 · Cited by 120
The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology
Mao, Y.-Q., & Houry, W. A. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00058 · Cited by 127
Yu, Q., Huang, T., Liu, C., Zhao, M., Xie, M., Li, G., Liu, S., Huang, W., & Zhao, Q. (2019) · Chemical Science · doi:10.1039/c9sc03161h · Cited by 112
Stromal Estrogen Receptor-α Promotes Tumor Growth by Normalizing an Increased Angiogenesis
Péqueux, C., Raymond-Letron, I., Blacher, S., Boudou, F., Adlanmerini, M., Fouque, M.-J., Rochaix, P., Noël, A., Foidart, J.-M., Krust, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3768 · Cited by 112
Vadde, R., Sarojamma, V., Jinka, R., Merchant, N., Bramhachari, P. V., & Nagaraju, G. P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.025 · Cited by 121
Meng, Z., Chao, Y., Zhou, X., Liang, C., Liu, J., Zhang, R., Cheng, L., Yang, K., Pan, W., Zhu, M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04544 · Cited by 118
Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., Guise, C. P., Smaill, J. B., Patterson, A. V., Lambin, P., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.01.005 · Cited by 111
Hypoxia-responsive nanoparticles for tumor-targeted drug delivery
Li, Y., Jeon, J., & Park, J. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.032 · Cited by 115
Liu, X.-Q., Xiong, M.-H., Shu, X.-T., Tang, R.-Z., & Wang, J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300193f · Cited by 111
Suzuki, T., Shinjo, S., Arai, T., Kanai, M., & Goda, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15087 · Cited by 119
King, A., Gellineau, H. A., Ahn, J.-E., MacMillan, S. N., & Wilson, J. J. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b00710 · Cited by 113
Zhou, X., Chen, J., Yi, G., Deng, M., Liu, H., Liang, M., Shi, B., Fu, X., Chen, Y., Chen, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6418 · Cited by 109
The Different Routes to Metastasis via Hypoxia-Regulated Programs
Nobre, A. R., Entenberg, D. R., Wang, Y., Condeelis, J. S., & Aguirre‐Ghiso, J. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.06.008 · Cited by 111
Size-Tunable Assemblies Based on Ferrocene-Containing DNA Polymers for Spatially Uniform Penetration
Tan, J., Li, H., Hu, X., Abdullah, R., Xie, S., Zhang, L., Zhao, M., Luo, Q., Li, Y., Sun, Z., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.05.024 · Cited by 111
A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth
Wang, X., Li, L., Zhao, K., Lin, Q., Li, H., Xue, X., Ge, W., He, H., Liu, D., Xie, H., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0449-8 · Cited by 122
Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis
Ghaemmaghami, A. B., Mahjoubin‐Tehran, M., Movahedpour, A., Morshedi, K., Sheida, A., Taghavi, S. P., Mirzaei, H., & Hamblin, M. R. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00623-9 · Cited by 112
Theranostic Nanomedicine for Synergistic Chemodynamic Therapy and Chemotherapy of Orthotopic Glioma
Tan, J., Duan, X., Zhang, F., Ban, X., Mao, J., Cao, M., Han, S., Shuai, X., & Shen, J. (2020) · Advanced Science · doi:10.1002/advs.202003036 · Cited by 114
Platinum(IV) antitumor complexes and their nano-drug delivery
Jia, C., Deacon, G. B., Zhang, Y., & Gao, C. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213640 · Cited by 112
Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma
Eckert, A. W., Wickenhauser, C., Salins, P. C., Kappler, M., Bukur, J., & Seliger, B. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0828-6 · Cited by 118
Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells
Alissafi, T., Hatzioannou, A., Mintzas, K., Barouni, R. M., Banos, A., Sormendi, S., Polyzos, A., Xilouri, M., Wielockx, B., Gogas, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120888 · Cited by 117
Near-infrared off-on fluorescence probe activated by NTR for in vivo hypoxia imaging
Zheng, J., Shen, Y., Xu, Z., Yuan, Z., He, Y., Wei, C., Er, M., Yin, J., & Chen, H. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.08.014 · Cited by 108
Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells
Hajizadeh, F., Okoye, I., Esmaily, M., Chaleshtari, M. G., Masjedi, A., Azizi, G., Irandoust, M., Ghalamfarsa, G., & Jadidi‐Niaragh, F. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116952 · Cited by 112
Emerging links between endosomal pH and cancer
Ko, M., Quiñones-Hinojosa, A., & Rao, R. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09870-1 · Cited by 107
D'Amore, S., Vacca, M., Cariello, M., Graziano, G., D'Orazio, A., Salvia, R., Sasso, R. C., Sabbà, C., Palasciano, G., & Moschetta, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.003 · Cited by 107
“On the other hand, we confirmed the suppression of: F) sterol-C5-desaturase (SCD5 participates to cholesterol biosynthesis pathway, and cell proliferation networks [25]); G) interleukin-1 receptor-associated kinase 3 (IRAK3 is involved in the regulation of humoral immune response and in the NF-κB, and IL-8 signaling […”
BackgroundT-type calcium channels blockers as new tools in cancer therapies
Dziegielewska, B., Gray, L. S., & Dziegielewski, J. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1444-z · Cited by 115
MacEwan, S. R., & Chilkoti, A. (2012) · Nano Letters · doi:10.1021/nl301529p · Cited by 117
Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment
Yang, Y. P., Wu, H., Liu, B., & Liu, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114004 · Cited by 107
Engineering lactate-modulating nanomedicines for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00479h · Cited by 112
Tang, D., Wang, D., Yuan, Z., Xue, X., Zhang, Y., An, Y., Chen, J., Tu, M., Lu, Z., Wei, J., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27715 · Cited by 118
The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer
García-Hernández, L., García‐Ortega, M. B., Ruiz-Alcalá, G., Carrillo, E., Marchal, J. A., & García, M. Á. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010370 · Cited by 123
The Valley of Death in anticancer drug development: a reassessment
Adams, D. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.001 · Cited by 106
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis
Myszczyszyn, A., Czarnecka, A. M., Matak, D., Szymański, Ł., Lian, F., Kornakiewicz, A., Bartnik, E., Kukwa, W., Kiéda, C., & Szczylik, C. A. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9611-y · Cited by 124
Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 114
Role of Aquaporin 1 Signalling in Cancer Development and Progression
Tomita, Y., Dorward, H. S., Yool, A. J., Smith, E., Townsend, A. R., Price, T. J., & Hardingham, J. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020299 · Cited by 116
Faes, S., Demartines, N., & Dormond, O. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1726078 · Cited by 107
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 107
Cui, Y., Huang, Y., Wu, X., Zheng, M., Xia, Y., Fu, Z., Ge, H., Wang, S., & Xie, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27533 · Cited by 107
Li, R.-Q., Zhang, C., Xie, B.-R., Yu, W.-Y., Qiu, W.-X., Cheng, H., & Zhang, X.-Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.017 · Cited by 105
Liu, J., Wang, L., Shen, X., Gao, X., Chen, Y., Liu, H., Liu, Y., Yin, D., Liu, Y., Xu, W., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100907 · Cited by 105
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.